Study of Mesenchymal Stem Cells for Pediatric Perianal Fistulizing Crohn's Disease
Status:
Recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
This study plans to enroll 10 patients aged 13-17 years of age with refractory perianal
fistulizing disease. Patients will be treated by direct injection to the fistula tract(s)
with 75 million allogeneic bone marrow derived mesenchymal stem cells at baseline and again
after 3 months if not completely healed.